JP2018522072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522072A5 JP2018522072A5 JP2018525531A JP2018525531A JP2018522072A5 JP 2018522072 A5 JP2018522072 A5 JP 2018522072A5 JP 2018525531 A JP2018525531 A JP 2018525531A JP 2018525531 A JP2018525531 A JP 2018525531A JP 2018522072 A5 JP2018522072 A5 JP 2018522072A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- vivo
- cancer
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 210000004986 primary T-cell Anatomy 0.000 claims 14
- 108020005004 Guide RNA Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 6
- 230000037442 genomic alteration Effects 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- ALNDFFUAQIVVPG-NGJCXOISSA-N (2r,3r,4r)-3,4,5-trihydroxy-2-methoxypentanal Chemical compound CO[C@@H](C=O)[C@H](O)[C@H](O)CO ALNDFFUAQIVVPG-NGJCXOISSA-N 0.000 claims 3
- 150000004713 phosphodiesters Chemical class 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108091008875 B cell receptors Proteins 0.000 claims 2
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 claims 2
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims 2
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 claims 2
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150043532 CISH gene Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021149724A JP2022000036A (ja) | 2015-07-31 | 2021-09-14 | 改変された細胞および治療の方法 |
| JP2023171191A JP2024001104A (ja) | 2015-07-31 | 2023-10-02 | 改変された細胞および治療の方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199905P | 2015-07-31 | 2015-07-31 | |
| US62/199,905 | 2015-07-31 | ||
| US201562232983P | 2015-09-25 | 2015-09-25 | |
| US62/232,983 | 2015-09-25 | ||
| US201662286206P | 2016-01-22 | 2016-01-22 | |
| US62/286,206 | 2016-01-22 | ||
| US201662295670P | 2016-02-16 | 2016-02-16 | |
| US62/295,670 | 2016-02-16 | ||
| US201662330464P | 2016-05-02 | 2016-05-02 | |
| US62/330,464 | 2016-05-02 | ||
| US201662360245P | 2016-07-08 | 2016-07-08 | |
| US62/360,245 | 2016-07-08 | ||
| PCT/US2016/044858 WO2017023803A1 (en) | 2015-07-31 | 2016-07-29 | Modified cells and methods of therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021149724A Division JP2022000036A (ja) | 2015-07-31 | 2021-09-14 | 改変された細胞および治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522072A JP2018522072A (ja) | 2018-08-09 |
| JP2018522072A5 true JP2018522072A5 (OSRAM) | 2019-09-05 |
| JP7409773B2 JP7409773B2 (ja) | 2024-01-09 |
Family
ID=57943822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525531A Active JP7409773B2 (ja) | 2015-07-31 | 2016-07-29 | 改変された細胞および治療の方法 |
| JP2021149724A Pending JP2022000036A (ja) | 2015-07-31 | 2021-09-14 | 改変された細胞および治療の方法 |
| JP2023171191A Pending JP2024001104A (ja) | 2015-07-31 | 2023-10-02 | 改変された細胞および治療の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021149724A Pending JP2022000036A (ja) | 2015-07-31 | 2021-09-14 | 改変された細胞および治療の方法 |
| JP2023171191A Pending JP2024001104A (ja) | 2015-07-31 | 2023-10-02 | 改変された細胞および治療の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (13) | US10166255B2 (OSRAM) |
| EP (2) | EP4339287A3 (OSRAM) |
| JP (3) | JP7409773B2 (OSRAM) |
| CN (1) | CN108472314A (OSRAM) |
| CA (1) | CA2993431A1 (OSRAM) |
| GB (3) | GB2595063B (OSRAM) |
| IL (2) | IL295616A (OSRAM) |
| WO (2) | WO2017023803A1 (OSRAM) |
Families Citing this family (196)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| CA2912678C (en) | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| AU2015249554B2 (en) | 2014-04-23 | 2021-08-19 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| JP6687544B2 (ja) | 2014-05-28 | 2020-04-22 | チルドレンズ ホスピタル メディカル センター | 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| WO2016012623A1 (en) * | 2014-07-25 | 2016-01-28 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| JP6895380B2 (ja) | 2015-02-06 | 2021-06-30 | ナショナル ユニバーシティ オブ シンガポール | 治療免疫細胞の有効性を改良するための方法 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| AU2016333898B2 (en) | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
| BR112018008971A2 (pt) * | 2015-11-06 | 2018-11-27 | Crispr Therapeutics Ag | materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a |
| SG11201808831TA (en) | 2016-04-15 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JP7193862B2 (ja) | 2016-08-03 | 2022-12-21 | ワシントン・ユニバーシティ | キメラ抗原受容体でのｔ細胞性悪性腫瘍の治療のためのｃａｒ－ｔ細胞の遺伝子編集 |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| JP7050215B2 (ja) * | 2016-08-19 | 2022-04-08 | ツールゲン インコーポレイテッド | 人工的に操作された血管新生調節系 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US10724043B2 (en) * | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| JP7588390B2 (ja) | 2016-10-14 | 2024-11-22 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのａａｖ送達 |
| CA3041068A1 (en) * | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響による親和性細胞抽出 |
| CN110023490B (zh) * | 2016-10-19 | 2024-08-09 | 塞勒克提斯公司 | 用于改善的免疫细胞疗法的靶向基因插入 |
| WO2018081476A2 (en) * | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
| SG11201903697WA (en) | 2016-11-04 | 2019-05-30 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| NZ753794A (en) * | 2016-11-07 | 2023-05-26 | Genovie Ab | An engineered multi-component system for identification and characterisation of t-cell receptors, t-cell antigens and their functional interaction |
| US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US20180221463A1 (en) * | 2017-01-13 | 2018-08-09 | The Chinese University Of Hong Kong | Modified NK Cells and Uses Thereof |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| US11629340B2 (en) * | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| BR112019019655A2 (pt) | 2017-03-23 | 2020-04-22 | Harvard College | editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico |
| US20200377881A1 (en) * | 2017-03-24 | 2020-12-03 | President And Fellows Of Harvard College | Methods of Genome Engineering by Nuclease-Transposase Fusion Proteins |
| WO2018191673A1 (en) | 2017-04-14 | 2018-10-18 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| JP2020517259A (ja) * | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| US20200190541A1 (en) * | 2017-04-28 | 2020-06-18 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| WO2018204493A1 (en) * | 2017-05-04 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for gene editing in t cells using crispr/cpf1 |
| JP7356354B2 (ja) * | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用 |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP2020528046A (ja) * | 2017-06-23 | 2020-09-17 | イエール ユニバーシティ | Ｔ細胞に基づく免疫療法の有効性増強のための組成物および方法 |
| WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物 |
| CN107475292B (zh) * | 2017-08-02 | 2018-06-15 | 山东百福基因科技有限公司 | Pd-1基因缺陷型t淋巴细胞制剂的制备方法 |
| US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| AU2018329741B2 (en) | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| WO2019047932A1 (zh) * | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| CN109628493B (zh) * | 2017-10-09 | 2021-12-07 | 广东赤萌医疗科技有限公司 | 一种用于制备可异体移植t细胞的基因编辑系统 |
| JP2020536529A (ja) | 2017-10-10 | 2020-12-17 | チルドレンズ ホスピタル メディカル センター | 食道組織および／または臓器組成物およびそれを作製する方法 |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| AU2018353112B2 (en) * | 2017-10-19 | 2024-11-14 | Cellectis | Targeted gene integration of NK inhibitors genes for improved immune cells therapy |
| KR20200075000A (ko) * | 2017-11-01 | 2020-06-25 | 에디타스 메디신, 인코포레이티드 | 면역요법을 위한 t 세포 내 tgfbr2의 crispr-cas9 편집 방법, 조성물 및 성분 |
| PL3704230T3 (pl) * | 2017-11-01 | 2025-02-24 | Juno Therapeutics, Inc. | Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie |
| CN111565730B (zh) * | 2017-11-09 | 2024-09-17 | 桑格摩生物治疗股份有限公司 | 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰 |
| JP7557367B2 (ja) * | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細針吸引及び小生検からのｔｉｌ拡大培養 |
| CN109837244A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用 |
| EP3724326A1 (en) * | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| AU2019227700B2 (en) | 2018-03-01 | 2025-09-11 | University Of Kansas | Techniques for generating cell-based therapeutics using recombinant T cell receptor genes |
| WO2019178225A2 (en) | 2018-03-13 | 2019-09-19 | Regents Of The University Of Minnesota | Lymphohematopoietic engineering using cas9 base editors |
| JP7304888B2 (ja) | 2018-04-12 | 2023-07-07 | プレシジョン バイオサイエンシズ，インク． | ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ |
| WO2019210279A1 (en) * | 2018-04-27 | 2019-10-31 | The Regents Of The University Of California | De novo formation of the biliary system by hepatocyte transdifferentiation |
| SG11202010763VA (en) * | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
| EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
| CA3100045A1 (en) * | 2018-05-11 | 2019-11-14 | The Regents Of The University Of California | Modification of immune cells to increase activity |
| WO2019222503A1 (en) * | 2018-05-16 | 2019-11-21 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| KR20210045360A (ko) | 2018-05-16 | 2021-04-26 | 신테고 코포레이션 | 가이드 rna 설계 및 사용을 위한 방법 및 시스템 |
| KR20210008408A (ko) | 2018-05-23 | 2021-01-21 | 싱가포르국립대학교 | T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2019246261A1 (en) * | 2018-06-19 | 2019-12-26 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| WO2020023361A1 (en) * | 2018-07-23 | 2020-01-30 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Enhancing anti-tumor response in melanoma cells with defective sting signaling |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| CN109593771B (zh) * | 2018-07-27 | 2022-03-29 | 四川大学华西医院 | 一种人类map2k5第1100位碱基突变基因及其检测试剂盒 |
| JP2021533797A (ja) * | 2018-08-21 | 2021-12-09 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co. LLC | 細胞質ｄｎａセンサー経路の下方制御 |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| AU2019339410A1 (en) | 2018-09-12 | 2021-04-15 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| WO2020055187A1 (ko) * | 2018-09-12 | 2020-03-19 | 기초과학연구원 | 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법 |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| CN111004781A (zh) * | 2018-10-08 | 2020-04-14 | 南加利福尼亚大学 | 长期扩增粒细胞-巨噬细胞祖细胞的方法及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020080475A1 (ja) * | 2018-10-18 | 2020-04-23 | 武田薬品工業株式会社 | Ｔ細胞の活性化／増殖方法 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| CA3121027A1 (en) * | 2018-11-28 | 2020-06-04 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| CN111349615B (zh) * | 2018-12-24 | 2024-08-13 | 上海细胞治疗集团股份有限公司 | 制备过表达外源基因的细胞的方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020215725A1 (en) * | 2019-02-01 | 2021-09-23 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| EP3924495A4 (en) * | 2019-02-12 | 2023-05-17 | Provincial Health Services Authority | COMPOSITIONS AND METHODS FOR ENHANCED LYMPHOCYTE-MEDIATED IMMUNOTHERAPY |
| IL316576A (en) * | 2019-02-12 | 2024-12-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| PH12021552003A1 (en) | 2019-02-15 | 2022-12-05 | Editas Medicine Inc | Modified natural killer (nk) cells for immunotherapy |
| CN109777782A (zh) * | 2019-02-15 | 2019-05-21 | 北京门罗生物科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
| EP3942042A1 (en) * | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US20220175848A1 (en) * | 2019-04-01 | 2022-06-09 | The Broad Institute, Inc. | Methods and compositions for cell therapy |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110144348A (zh) * | 2019-04-22 | 2019-08-20 | 江苏医药职业学院 | 用于敲低DEAH盒解旋酶16表达的siRNA、重组载体及其应用 |
| CN113939319A (zh) | 2019-04-30 | 2022-01-14 | 克里斯珀医疗股份公司 | 靶向cd19的基因工程化t细胞针对b细胞恶性肿瘤的同种异体细胞疗法 |
| JP7610533B2 (ja) | 2019-05-31 | 2025-01-08 | チルドレンズ ホスピタル メディカル センター | 造血幹細胞の生成および拡大方法 |
| AU2020286493A1 (en) * | 2019-06-01 | 2022-01-27 | Sivec Biotechnologies, Llc | A bacterial platform for delivery of gene-editing systems to eukaryotic cells |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
| GB201908729D0 (en) * | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
| WO2021007089A1 (en) * | 2019-07-08 | 2021-01-14 | Pillargo, Inc. | Homologous recombination directed genome editing in eukaryotes |
| EP4025686A4 (en) | 2019-09-03 | 2023-09-13 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US20220288202A1 (en) * | 2019-09-04 | 2022-09-15 | Cedars-Sinai Medical Center | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients |
| BR112022004031A2 (pt) | 2019-09-05 | 2022-08-16 | Crispr Therapeutics Ag | Células doadoras universais |
| EP4034659A4 (en) * | 2019-09-27 | 2024-10-16 | The Broad Institute, Inc. | PROGRAMMABLE POLYNUCLEOTIDE EDITORS FOR AMPLIFIED HOMOLOGOUS RECOMBINATION |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| WO2021092593A1 (en) * | 2019-11-08 | 2021-05-14 | The University Of North Carolina At Chapel Hill | Use of agonists to augment car t function in solid tumors |
| AR120563A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quimérico cd19 y cd22 y sus usos |
| CN115003801A (zh) * | 2019-11-27 | 2022-09-02 | 得克萨斯大学体系董事会 | 用于克服肿瘤微环境中的免疫抑制的改造的t细胞和肿瘤浸润性淋巴细胞 |
| AU2020408017A1 (en) | 2019-12-20 | 2022-07-14 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| CN110964744A (zh) * | 2019-12-23 | 2020-04-07 | 湖南普拉特泽生物科技有限公司 | 一种能稳定表达Cas9蛋白的人骨肉瘤U-2OS工具细胞株及其制备方法与应用 |
| CN110951782A (zh) * | 2019-12-23 | 2020-04-03 | 湖南普拉特网络科技有限公司 | 一种能稳定表达Cas9蛋白的细胞株及其制备方法与应用 |
| AU2021265797A1 (en) | 2020-04-28 | 2022-12-08 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN111420025B (zh) * | 2020-04-28 | 2021-06-11 | 中国药科大学 | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 |
| EP4146812A1 (en) * | 2020-05-06 | 2023-03-15 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN112063620A (zh) * | 2020-06-16 | 2020-12-11 | 中国人民解放军陆军军医大学 | 抑制猪流行性腹泻病毒M基因表达的shRNA |
| CN115997015A (zh) * | 2020-06-26 | 2023-04-21 | 美国杰特贝林生物制品有限公司 | 具有杀伤开关的供体t细胞 |
| WO2022026921A1 (en) * | 2020-07-30 | 2022-02-03 | Repertoire Immune Medicines, Inc. | Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19 |
| KR20230074515A (ko) | 2020-09-23 | 2023-05-30 | 크리스퍼 테라퓨틱스 아게 | 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포 |
| WO2022083667A1 (en) * | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Polypeptides comprising a vaccine specific tcr and a chimeric antigen receptor and uses thereof |
| EP4196490A4 (en) * | 2020-10-27 | 2025-02-26 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| CN114457031A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达b7-h5阻断物的多能干细胞或其衍生物及应用 |
| JP2023550490A (ja) | 2020-11-23 | 2023-12-01 | ライエル・イミュノファーマ・インコーポレイテッド | 免疫細胞を培養するための方法 |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| CA3201621A1 (en) | 2020-12-03 | 2022-06-09 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| US11578309B2 (en) | 2020-12-31 | 2023-02-14 | Crispr Therapeutics Ag | Universal donor cells |
| CN112941105A (zh) * | 2021-02-08 | 2021-06-11 | 江西农业大学 | 一种m6A“阅读器”YTHDF2基因改造方法及其应用 |
| CN112746098A (zh) * | 2021-02-22 | 2021-05-04 | 深圳荻硕贝肯精准医学有限公司 | Kir2dl2基因分型试剂盒和分型方法 |
| AU2022226660A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN113249382B (zh) * | 2021-04-12 | 2023-05-12 | 右江民族医学院 | 下调TRIM56基因表达的siRNA及其应用 |
| JP2024518100A (ja) | 2021-05-11 | 2024-04-24 | マイエロイド・セラピューティクス，インコーポレーテッド | ゲノム組込みのための方法および組成物 |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| WO2022267843A1 (en) * | 2021-06-21 | 2022-12-29 | Westlake University | Library construction method based on long overhang sequence ligation |
| US20240301092A1 (en) * | 2021-06-29 | 2024-09-12 | Tega Therapeutics, Inc. | Heparin from modified mst cells and methods of making and using |
| CN113481184A (zh) * | 2021-08-06 | 2021-10-08 | 北京大学 | 融合蛋白以及其使用方法 |
| CN118056012B (zh) * | 2021-08-24 | 2025-05-30 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| WO2023060217A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers |
| CN114196604B (zh) * | 2021-10-09 | 2024-01-23 | 上海交通大学医学院附属仁济医院 | 一种双重修饰的工程化细菌及其应用 |
| JP2024540106A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | 免疫細胞を培養するための方法 |
| CN114058619B (zh) * | 2021-11-19 | 2023-11-14 | 中国农业科学院兰州兽医研究所 | Riplet敲除细胞系的构建及作为小核糖核酸病毒科病毒疫苗生产细胞系的应用 |
| CN116162621B (zh) * | 2021-11-25 | 2025-09-16 | 中国科学院大连化学物理研究所 | Dna双链序列及应用和肺腺癌细胞增殖抑制剂或在肺腺癌药物 |
| EP4583890A1 (en) * | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| KR20250143881A (ko) | 2023-01-12 | 2025-10-02 | 내셔널 유니버시티 오브 싱가포르 | T 세포 및 nk 세포 악성종양의 면역요법을 위한 cd8 발현 차단 및 키메라 항원 수용체 |
| TW202503051A (zh) * | 2023-03-07 | 2025-01-16 | 美商英特利亞醫療公司 | 用於免疫療法之ｃｉｓｈ組合物及方法 |
| WO2024206911A2 (en) | 2023-03-30 | 2024-10-03 | Children's Hospital Medical Center | Clinical-grade organoids |
| WO2024238977A2 (en) | 2023-05-18 | 2024-11-21 | Children's Hospital Medical Center | Liver organoids with intrahepatic sympathetic nerves, and methods of use thereof |
| WO2024263961A2 (en) | 2023-06-23 | 2024-12-26 | Children's Hospital Medical Center | Methods of matrix-free suspension culture |
| WO2025006811A1 (en) | 2023-06-27 | 2025-01-02 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
| WO2025049816A1 (en) * | 2023-08-30 | 2025-03-06 | Full Circles Therapeutics Inc. | Method for engineering of immune cells expressing chimeric antigen receptors at immune checkpoint loci for disease treatment |
| WO2025072803A1 (en) | 2023-09-29 | 2025-04-03 | Children's Hospital Medical Center | Ntrk2 signaling-mediated alveolar capillary injury and repair |
| WO2025179160A1 (en) * | 2024-02-21 | 2025-08-28 | Research Institute At Nationwide Children's Hospital | Methods of increasing nk cell efficacy through inhibition of v-domain ig suppressor of t cell activation (vista) |
| WO2025212920A1 (en) | 2024-04-03 | 2025-10-09 | Children's Hospital Medical Center | Multi-zonal liver organoids |
| WO2025217202A1 (en) | 2024-04-08 | 2025-10-16 | Children's Hospital Medical Center | Bile duct organoid |
Family Cites Families (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| EP0752005B1 (en) | 1994-03-23 | 2008-10-08 | Ohio University | Compacted nucleic acids and their delivery to cells |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| JP2001517206A (ja) | 1996-08-16 | 2001-10-02 | ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン | 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 |
| DE69718029T2 (de) | 1996-10-11 | 2003-10-16 | The Regents Of The University Of California, Oakland | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| DE69941905D1 (de) | 1998-11-10 | 2010-02-25 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2361191A1 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| JP2000256212A (ja) | 1999-03-05 | 2000-09-19 | Tadayasu Takada | 良性間葉系腫瘍の治療剤 |
| EP1252309A2 (en) | 2000-01-28 | 2002-10-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| WO2001068888A2 (en) | 2000-03-14 | 2001-09-20 | Neurologix, Inc. | Production of chimeric capsid vectors |
| CA2425194A1 (en) | 2000-10-09 | 2002-04-18 | Andrew Nash | Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal |
| US8716022B2 (en) | 2000-11-17 | 2014-05-06 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Modulation of meiotic recombination |
| US7723111B2 (en) | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| AU2003216436A1 (en) | 2002-02-08 | 2003-09-02 | Life Technologies Corporation | Compositions and methods for restoring immune responsiveness in patients with immunological defects |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| AU2003233734C1 (en) * | 2002-06-05 | 2011-01-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Retrons for gene targeting |
| EP3910063A1 (en) | 2003-09-30 | 2021-11-17 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005113595A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | High affinity ny-eso t cell receptor |
| ATE408684T1 (de) | 2004-05-19 | 2008-10-15 | Medigene Ltd | Verfahren zur verbesserung von t-zellrezeptoren |
| AU2005266225A1 (en) | 2004-06-25 | 2006-02-02 | Centre National De La Recherche Scientifique | Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle |
| CN101437834B (zh) | 2004-07-19 | 2012-06-06 | 贝勒医学院 | 细胞因子信号转导调节剂的调节和用于免疫治疗的应用 |
| US8889365B2 (en) | 2005-03-16 | 2014-11-18 | Rutgers, The State University Of New Jersey | Methods and kit for detecting breast cancer |
| EP3409296A1 (en) | 2005-04-07 | 2018-12-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
| US8389708B2 (en) | 2005-06-15 | 2013-03-05 | Weiping Min | Method of cancer treatment using siRNA silencing |
| DK1910521T3 (da) | 2005-08-05 | 2011-02-07 | Helmholtz Zentrum Muenchen | Generering af allo-begrænsede, antigenspecifikke T-celler |
| DK2341149T3 (en) | 2005-08-26 | 2017-02-27 | Dupont Nutrition Biosci Aps | Use of CRISPR-associated genes (Cas) |
| US20090220488A1 (en) | 2005-08-31 | 2009-09-03 | Humphrey Gardner | Evaluating and treating scleroderma |
| GB0602547D0 (en) | 2006-02-08 | 2006-03-22 | Nanotecture Ltd | Improved electrochemical cell construction |
| BRPI0712073B8 (pt) | 2006-05-17 | 2021-05-25 | Hoffmann La Roche | ácido nucléico para produção de um polipeptídio ou proteína heteróloga |
| EP2426220B1 (en) | 2006-05-19 | 2016-06-22 | DuPont Nutrition Biosciences ApS | Tagged microorganisms and methods of tagging |
| EP1878744A1 (en) | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| JP5543207B2 (ja) | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| JP2008166438A (ja) | 2006-12-27 | 2008-07-17 | Spansion Llc | 半導体装置およびその製造方法 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| US7750449B2 (en) | 2007-03-13 | 2010-07-06 | Micron Technology, Inc. | Packaged semiconductor components having substantially rigid support members and methods of packaging semiconductor components |
| EP2856876B1 (en) | 2007-03-30 | 2018-01-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| EP2281050B1 (en) | 2008-04-14 | 2014-04-02 | Sangamo BioSciences, Inc. | Linear donor constructs for targeted integration |
| WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US20120192298A1 (en) | 2009-07-24 | 2012-07-26 | Sigma Aldrich Co. Llc | Method for genome editing |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011117258A2 (en) | 2010-03-22 | 2011-09-29 | Association Institut De Myologie | Methods of increasing efficiency of vector penetration of target tissue |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| ES2656414T3 (es) * | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| WO2012078540A1 (en) * | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012112079A1 (en) | 2011-02-14 | 2012-08-23 | Vitaspero, Inc. | IMPROVING CELLULAR IMMUNOTHERAPEUTIC VACCINES EFFICACY WITH GENE SUPPRESSION IN DENDRITIC CELLS AND T-LYMPHOCYTES USING SiRNA |
| US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| EP2700399B1 (en) | 2011-04-18 | 2017-05-31 | National Center of Neurology and Psychiatry | Drug delivery particles and method for producing same |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| WO2012168944A1 (en) * | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| KR101307196B1 (ko) | 2011-07-15 | 2013-09-12 | 국립대학법인 울산과학기술대학교 산학협력단 | 미세 세포 배양 장치 |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| US9593338B2 (en) | 2011-09-28 | 2017-03-14 | The Regents Of The University Of California | Synthetic transcriptional control elements and methods of generating and using such elements |
| HK1201565A1 (en) | 2011-10-21 | 2015-09-04 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| JP6074435B2 (ja) | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| BR112014014591A8 (pt) | 2011-12-12 | 2017-07-04 | Baylor College Medicine | processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs |
| BR112014014105B1 (pt) | 2011-12-16 | 2023-10-10 | Targetgene Biotechnologies Ltd | Método para modificar um sítio-alvo predeterminado no interior de um ácido nucleico genômico ou organelar alvo em uma célula hospedeira eucariótica por um complexo núcleoproteína |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013177247A1 (en) | 2012-05-22 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Murine anti-ny-eso-1 t cell receptors |
| SI3401400T1 (sl) | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| DK3473707T3 (da) | 2012-05-25 | 2025-03-17 | Cellectis | Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| WO2014006518A1 (en) | 2012-07-04 | 2014-01-09 | Indian Institute Of Science | Compounds as inhibitor of dna double-strand break repair, methods and applications thereof |
| CN105188767A (zh) | 2012-07-25 | 2015-12-23 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| HK1207111A1 (en) | 2012-08-03 | 2016-01-22 | 加利福尼亚大学董事会 | Methods and compositions for controlling gene expression by rna processing |
| IL293944A (en) | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| HK1217732A1 (zh) * | 2012-09-07 | 2017-01-20 | 美国陶氏益农公司 | Fad3性能基因座及相應的能夠誘導靶向斷裂的靶位點特異性結合蛋白 |
| EP2906684B8 (en) * | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US20140113375A1 (en) * | 2012-10-21 | 2014-04-24 | Lixin Liu | Transient Expression And Reverse Transcription Aided Genome Alteration System |
| SG11201503059XA (en) | 2012-10-23 | 2015-06-29 | Toolgen Inc | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| EP3138911B1 (en) | 2012-12-06 | 2018-12-05 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| BR112015013784A2 (pt) * | 2012-12-12 | 2017-07-11 | Massachusetts Inst Technology | aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2701749T3 (es) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| CN105658796B (zh) | 2012-12-12 | 2021-10-26 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| ES2536353T3 (es) | 2012-12-12 | 2015-05-22 | The Broad Institute, Inc. | Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias |
| DK3553174T3 (da) | 2012-12-17 | 2025-08-04 | Harvard College | Rna-guided modificering af humant genom |
| WO2014110591A1 (en) * | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| EP2958996B1 (en) | 2013-02-25 | 2019-10-16 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| MY175869A (en) | 2013-02-26 | 2020-07-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP2922393B2 (en) | 2013-02-27 | 2022-12-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
| US9393257B2 (en) | 2013-03-01 | 2016-07-19 | Regents Of The University Of Minnesota | TALEN-based gene correction |
| US20140315985A1 (en) | 2013-03-14 | 2014-10-23 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
| US20160138027A1 (en) | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| US9885033B2 (en) | 2013-03-15 | 2018-02-06 | The General Hospital Corporation | Increasing specificity for RNA-guided genome editing |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| AU2014235968B2 (en) | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用 |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| WO2014184744A1 (en) * | 2013-05-13 | 2014-11-20 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| HK1223401A1 (zh) | 2013-05-15 | 2017-07-28 | 桑格摩生物科学股份有限公司 | 用於治疗遗传病状的方法和组合物 |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| ES2645393T3 (es) * | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
| ES2670531T3 (es) | 2013-05-29 | 2018-05-30 | Cellectis S.A. | Un método para producir una escisión de ADN precisa utilizando la actividad nickasa de Cas9 |
| JP6195474B2 (ja) | 2013-05-31 | 2017-09-13 | ギガフォトン株式会社 | 極端紫外光生成装置及び極端紫外光生成システムにおけるレーザシステムの制御方法 |
| EP3011033B1 (en) | 2013-06-17 | 2020-02-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| DK3011031T3 (da) | 2013-06-17 | 2020-12-21 | Broad Inst Inc | Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi |
| KR20250012194A (ko) | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| EP3011030B1 (en) | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| CN105683379A (zh) | 2013-06-17 | 2016-06-15 | 布罗德研究所有限公司 | 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化 |
| JP6625971B2 (ja) | 2013-06-17 | 2019-12-25 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化 |
| JPWO2015002293A1 (ja) | 2013-07-05 | 2017-02-23 | 学校法人 岩手医科大学 | Ｗｎｔシグナル阻害剤 |
| JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用 |
| SG11201600060VA (en) | 2013-07-10 | 2016-02-26 | Harvard College | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
| WO2015006774A2 (en) | 2013-07-12 | 2015-01-15 | Oms Investments, Inc. | Plants comprising events pp009-401, pp009-415, and pp009-469, compositions, sequences, and methods for detection thereof |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| CA3109801C (en) | 2013-08-22 | 2024-01-09 | Andrew Cigan | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
| CN104427476B (zh) | 2013-09-10 | 2019-05-07 | 中兴通讯股份有限公司 | 位置信息上报方法、集群服务处理方法及系统 |
| WO2015048690A1 (en) | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Optimized small guide rnas and methods of use |
| US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| DE102013111099B4 (de) | 2013-10-08 | 2023-11-30 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA |
| US20150098954A1 (en) | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
| CA2930015A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| CA2928635C (en) | 2013-11-28 | 2022-06-21 | Horizon Genomics Gmbh | Somatic haploid human cell line |
| WO2015084897A2 (en) | 2013-12-02 | 2015-06-11 | Mirimmune, Llc | Immunotherapy of cancer |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| WO2015089351A1 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
| JP2017501149A (ja) | 2013-12-12 | 2017-01-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用 |
| AU2014368982B2 (en) * | 2013-12-19 | 2021-03-25 | Amyris, Inc. | Methods for genomic integration |
| EP3105317B1 (en) | 2014-02-14 | 2018-09-19 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CN103820454B (zh) | 2014-03-04 | 2016-03-30 | 上海金卫生物技术有限公司 | CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| KR20250004905A (ko) | 2014-03-20 | 2025-01-08 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 입양 세포 요법을 위한 종양-침윤 림프구 |
| JP2017512481A (ja) | 2014-04-08 | 2017-05-25 | ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ | Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物 |
| EP3129488B1 (en) | 2014-04-10 | 2019-06-12 | The Regents of The University of California | Methods and compositions for using argonaute to modify a single stranded target nucleic acid |
| EP3800248A3 (en) | 2014-04-18 | 2021-08-04 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| AU2015249554B2 (en) | 2014-04-23 | 2021-08-19 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| EP3152319A4 (en) | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
| CA2951707A1 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| US20170224731A1 (en) | 2014-06-10 | 2017-08-10 | Monash University | Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer |
| TWI530276B (zh) | 2014-07-08 | 2016-04-21 | 原相科技股份有限公司 | 具去噪功能之生理偵測模組及其生理偵測方法 |
| MX2017000646A (es) | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| WO2016036754A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification |
| EP3193892A4 (en) | 2014-09-14 | 2018-09-12 | Washington University | Personalized cancer vaccines and methods therefor |
| AU2015317793B2 (en) | 2014-09-16 | 2021-11-11 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
| KR102630014B1 (ko) | 2014-10-01 | 2024-01-25 | 더 제너럴 하스피탈 코포레이션 | 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법 |
| CA2963362A1 (en) | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| AU2015339743C1 (en) | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| EP3018200A1 (en) | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| CN107250148B (zh) | 2014-12-03 | 2021-04-16 | 安捷伦科技有限公司 | 具有化学修饰的指导rna |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| US11339399B2 (en) * | 2014-12-31 | 2022-05-24 | Viridos, Inc. | Compositions and methods for high efficiency in vivo genome editing |
| CN107406842B (zh) | 2015-01-09 | 2021-05-11 | 生物辐射实验室股份有限公司 | 检测基因组编辑 |
| CN107429263A (zh) | 2015-01-15 | 2017-12-01 | 斯坦福大学托管董事会 | 调控基因组编辑的方法 |
| KR102422108B1 (ko) | 2015-01-20 | 2022-07-19 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 |
| US20190388469A1 (en) | 2015-01-30 | 2019-12-26 | The Regents Of The University Of California | Protein delivery in primary hematopoietic cells |
| JP7013240B2 (ja) | 2015-02-16 | 2022-01-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｈｅｒ２／Ｎｅｕ （ＥＲＢＢ２）受容体タンパク質に由来する３６９～３７７位エピトープに特異的な完全ヒトＴ細胞受容体 |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| US20180119174A1 (en) | 2015-05-13 | 2018-05-03 | Seattle Children's Hospita (dba Seattle Children's Research Institute | Enhancing endonuclease based gene editing in primary cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP4043556B1 (en) * | 2015-06-30 | 2024-02-07 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| EP3322297B1 (en) | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| MX2018003062A (es) | 2015-09-15 | 2018-09-11 | Us Health | Receptores de celula t que reconocen kras mutante restringido en hla-cw8. |
| CN112972492B (zh) | 2015-12-16 | 2024-11-08 | 沃尔特及伊莱萨霍尔医学研究院 | Nk细胞中对细胞因子诱导的sh2蛋白的抑制 |
| US9570114B1 (en) | 2016-01-15 | 2017-02-14 | HGST Netherlands B.V. | Laminated film-packed hard disk drive for hermetic sealing |
| WO2017139264A1 (en) | 2016-02-09 | 2017-08-17 | President And Fellows Of Harvard College | Dna-guided gene editing and regulation |
| US11091776B2 (en) | 2016-04-15 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | AAV8 mutant capsids and compositions containing same |
| WO2017214569A1 (en) | 2016-06-09 | 2017-12-14 | Regents Of The University Of Minnesota | Genome-edited nk cell and methods of making and using |
| CA3030156A1 (en) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| MX2019000643A (es) | 2016-07-15 | 2019-06-13 | Poseida Therapeutics Inc | Receptores de antigenos quimericos y metodos de uso. |
| CN106480027A (zh) | 2016-09-30 | 2017-03-08 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9 靶向敲除人PD‑1基因及其特异性gRNA |
| CA3041068A1 (en) | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| WO2018081476A2 (en) | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
| CA3045551A1 (en) | 2016-12-16 | 2018-06-21 | Uniqure Ip B.V. | Immunoadsorption |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| EP3679137A4 (en) | 2017-09-07 | 2021-06-02 | The Board of Trustees of the Leland Stanford Junior University | NUCLEASE SYSTEMS FOR GENE ENGINEERING |
| CN111565730B (zh) | 2017-11-09 | 2024-09-17 | 桑格摩生物治疗股份有限公司 | 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰 |
-
2016
- 2016-07-29 WO PCT/US2016/044858 patent/WO2017023803A1/en not_active Ceased
- 2016-07-29 WO PCT/US2016/044856 patent/WO2017023801A1/en not_active Ceased
- 2016-07-29 EP EP23211577.4A patent/EP4339287A3/en active Pending
- 2016-07-29 CN CN201680059180.8A patent/CN108472314A/zh active Pending
- 2016-07-29 GB GB2107650.0A patent/GB2595063B/en active Active
- 2016-07-29 US US15/224,151 patent/US10166255B2/en active Active
- 2016-07-29 US US15/224,159 patent/US20170119820A1/en not_active Abandoned
- 2016-07-29 JP JP2018525531A patent/JP7409773B2/ja active Active
- 2016-07-29 IL IL295616A patent/IL295616A/en unknown
- 2016-07-29 GB GB2107651.8A patent/GB2592821B/en active Active
- 2016-07-29 CA CA2993431A patent/CA2993431A1/en active Pending
- 2016-07-29 GB GB1803280.5A patent/GB2557123B/en active Active
- 2016-07-29 IL IL257105A patent/IL257105B/en unknown
- 2016-07-29 EP EP16833645.1A patent/EP3328399B1/en active Active
- 2016-08-29 US US15/250,514 patent/US10406177B2/en active Active
- 2016-09-02 US US15/256,086 patent/US11147837B2/en active Active
-
2018
- 2018-11-05 US US16/180,867 patent/US11903966B2/en active Active
- 2018-11-06 US US16/182,189 patent/US11642375B2/en active Active
- 2018-11-06 US US16/182,146 patent/US11642374B2/en active Active
-
2020
- 2020-06-12 US US16/900,363 patent/US20200306309A1/en not_active Abandoned
- 2020-06-12 US US16/900,368 patent/US11925664B2/en active Active
- 2020-06-12 US US16/900,372 patent/US11266692B2/en active Active
- 2020-08-26 US US17/003,081 patent/US11583556B2/en active Active
-
2021
- 2021-09-14 JP JP2021149724A patent/JP2022000036A/ja active Pending
- 2021-09-17 US US17/478,615 patent/US20220125843A1/en active Pending
-
2022
- 2022-02-17 US US17/674,378 patent/US20220362297A1/en active Pending
-
2023
- 2023-10-02 JP JP2023171191A patent/JP2024001104A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522072A5 (OSRAM) | ||
| CN107630006B (zh) | 一种制备tcr与hla双基因敲除的t细胞的方法 | |
| JP7459111B2 (ja) | 改変ｔ細胞、その調製方法および使用 | |
| JP6608807B2 (ja) | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 | |
| JP2019176869A5 (OSRAM) | ||
| Wang et al. | CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells | |
| WO2020092057A1 (en) | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells | |
| KR20190038479A (ko) | 유전자 조작된 세포 및 그의 제조방법 | |
| KR20240043810A (ko) | 세포 치료에 사용하기 위한 면역학적으로 식별 가능한 세포 표면 변이체 | |
| Afolabi et al. | Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy | |
| JP2018537112A5 (OSRAM) | ||
| JP2016539929A5 (OSRAM) | ||
| AU2019376903A1 (en) | Anti-LIV1 immune cell cancer therapy | |
| Sim et al. | Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development | |
| CN116583607A (zh) | 用于工程改造和选择具有期望表型的car t细胞的组合物和方法 | |
| Yi et al. | Stem-like T cells and niches: Implications in human health and disease | |
| WO2022093846A1 (en) | Safe harbor loci | |
| Gress et al. | Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation | |
| Fang et al. | Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy | |
| Kath et al. | CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products | |
| JP2023532917A (ja) | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 | |
| US20240307444A1 (en) | Methods and compositions for improved immunotherapies | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| EP4405464A2 (en) | Methods and composition using patient-derived autologous neoantigens for treating cancer | |
| JP2019508056A5 (OSRAM) |